Sionna Therapeutics Achieves Full Enrollment in Phase 2a CFTR Modulator Trial Ahead of Summer Readout

With two NBD1 stabilizer programs converging on summer 2026 topline readouts, Sionna Therapeutics is positioning contract manufacturers and formulation teams to prepare for potential scale-up decisions on a novel class of CFTR modulators that targets protein stability rather than the transmembrane or gating mechanisms addressed by existing therapies. Enrollment completion in the PreciSION CF Phase 2a proof-of-concept trial evaluating SION-719 was confirmed in April 2026, with topline safety, tolerability, pharmacokinetic, and sweat chloride data anticipated this summer.

The parallel Phase 1 trial (NCT07035990) is evaluating SION-451 in proprietary dual combinations: one pairing with SION-2222 (galicaftor), a TMD1-directed corrector, and a second with SION-109, an ICL4-directed corrector. Both combinations are being assessed in healthy volunteers, with topline data also expected this summer. The dual-combination architecture introduces formulation complexity that CMOs should begin mapping now, particularly around drug-drug interaction profiling, compatibility testing, and the analytical method development required to characterize each molecular entity within a fixed or co-administered regimen.

For QA and regulatory leads, the Phase 2a design warrants attention: SION-719 is being evaluated as an add-on to standard of care, meaning participants are already on approved CFTR modulator regimens. That layered exposure profile will require robust PK bridging data and clear CAPA protocols if any safety signals emerge at the intersection of NBD1 stabilization and existing modulator therapy. Preclinical data presented at the 2025 NACFC, and set for encore presentation at the 49th European Cystic Fibrosis Conference (June 3-6, Lisbon), indicate that NBD1 stabilizers can extend F508del-CFTR protein half-life to wild-type levels, a mechanistic claim that regulators will scrutinize closely against clinical endpoints.

Sionna reported R&D expenditure of $19.0 million for Q1 2026, up from $13.7 million in the prior-year period, reflecting the increased clinical activity across both programs. Cash and equivalents stood at approximately $289.9 million, with runway projected into 2028, providing sufficient capital to advance through Phase 2 readouts and into potential Phase 3 planning without near-term financing pressure.

The summer topline readouts will serve as the first clinical validation checkpoint for the NBD1 stabilizer mechanism, with the sweat chloride endpoint in PreciSION CF offering a quantifiable early signal of CFTR functional restoration.

Source: Sionna Therapeutics, Inc. via GlobeNewswire, May 12, 2026.